Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Solriamfetol (Sunosi)

Notes:

- Quantity limits: Yes
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria and criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Nonformulary solriamfetol (Sunosi) will be covered on the prescription drug benefit for 12 months when the following criteria are met:

- Prescribed by a Sleep Specialist
- Prescribed for the treatment of excessive daytime sleepiness due to narcolepsy OR excessive daytime sleepiness due to obstructive sleep apnea (OSA) OR Idiopathic hypersomnia
- Patient is 18 years of age or older
- Patient has failed a trial of, or patient has an allergy or intolerance* to:
 - Modafinil or armodafinil AND
 - A stimulant medication (ie methylphenidate, dextroamphetamine, amphetamine salt combination, etc.)
- OSA only: patient is currently treated for OSA [i.e. use of CPAP, or use of oral appliances (eg mandibular advancement device, tongue retaining devices), or had past OSA surgery]

<u>Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously</u>: Non-formulary solriamfetol (Sunosi) will be covered on the prescription drug benefit for <u>12 months</u> when the following criteria are met:

- Prescribed for the treatment of excessive daytime sleepiness due to narcolepsy OR excessive daytime sleepiness due to obstructive sleep apnea (OSA) OR Idiopathic hypersomnia
- Patient is 18 years of age or older
- Patient has failed a trial of, or patient has an allergy or intolerance* to:
 - Modafinil or armodafinil AND
 - A stimulant medication (ie methylphenidate, dextroamphetamine, amphetamine salt combination, etc.)

kp.org

Revised: 10/14/21 Effective: 12/02/21 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Solriamfetol (Sunosi)

<u>Continued use criteria for patients stable on the medication</u>: Non-formulary solriamfetol (Sunosi) will continue to be covered on the prescription drug benefit for <u>24</u> months when the following criteria are met:

Continues to be prescribed by a Sleep Specialist

kp.org

Revised: 10/14/21 Effective: 12/02/21



